DDInter256 DDInter997
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Butabarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Butabarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Amobarbital
Amobarbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Butabarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Ivacaftor
Butabarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Butabarbital (Compound) resembles Secobarbital (Compound) and Secobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Butabarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)